sur ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)
OSE Immunotherapeutics: 2025 Financial Review and 2026 Outlook
OSE Immunotherapeutics has released its unaudited financial results for 2025, revealing operating revenues of €2.7 million, down from €83.4 million in 2024. This decrease is attributed to the absence of exceptional income received the previous year. Research expenditures increased by 11.5% to €33.9 million, reflecting the continuation of projects such as the Phase 3 trial of Tedopi®.
The net result shows a loss of €37.7 million compared to a profit of €37.4 million in 2024. The company had €17.6 million in cash at the end of 2025 and plans to secure its financing until the fourth quarter of 2026. A postponement of the filing of the 2025 Universal Registration Document has been announced, until May 2026. Alternative financing options and partnerships remain under consideration.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ORPHAN SYNERGY EUROPE-PHARMA